论文部分内容阅读
目的研究环氧化酶2抑制剂对人胃癌组织原位移植非肥胖性糖尿病(NOD)重度联合免疫缺陷(SC ID)小鼠转移模型的肿瘤转移抑制剂、血管生成和血管内皮生长因子(VEGF)表达的影响。方法建立人胃癌组织原位移植NOD SC ID小鼠胃癌转移模型,40只小鼠均分成两组。移植后1周,分别静脉注射0.9%氯化钠溶液(0.9%氯化钠溶液组)50 mg/(kg.d)环氧化酶2抑制剂(尼美舒利组),每周2次,共2周。第5周处死动物,观察肿瘤转移情况,免疫组化法检测肿瘤组织微血管密度、VEGF表达,荧光定量PCR检测肿瘤组织VEGF mRNA表达。结果0.9%氯化钠溶液组20只小鼠18只有肿瘤转移,尼美舒利组20只小鼠只有5只转移,两组间差异有统计学意义(P<0.05)。0.9%氯化钠溶液组平均微血管密度为9.5±2.9,尼美舒利组为3.9±2.1,两组间差异有统计学意义(P<0.05)。0.9%氯化钠溶液组18只小鼠VEGF阳性表达,明显高于尼美舒利组的5只(P<0.05)。荧光定量PCR测定显示,尼美舒利组VEGFmRNA(C t:20.1±2.0)表达较0.9%氯化钠溶液组(C t:15.9±1.8)低,两组间差异有统计学意义(尼美舒利,P<0.05)。结论环氧化酶2抑制剂尼美舒利通过抑制肿瘤组织VEGF表达和血管生成,抑制肿瘤转移,尼美舒利无明显出血等不良反应。
Objective To investigate the effects of cyclooxygenase-2 inhibitor on tumor metastasis, tumor angiogenesis and vascular endothelial growth factor (VEGF) in human gastric cancer tissue orthotopic transplantation of non-obese diabetic (NOD) combined immunodeficiency (SCID) ) Expression. Methods Gastric carcinoma metastasis model of NOD SCID mice was established by in situ transplantation of human gastric cancer tissue. All 40 mice were divided into two groups. One week after transplantation, rats were treated with 0.9% sodium chloride solution (0.9% sodium chloride solution) 50 mg / (kg.d) cyclooxygenase 2 inhibitor (nimesulide) twice a week , A total of 2 weeks. Animals were sacrificed at the fifth week, the tumor metastasis was observed, the microvessel density and VEGF expression in the tumor tissue were detected by immunohistochemistry, and the expression of VEGF mRNA in the tumor tissue was detected by the fluorescent quantitative PCR. Results Twenty - eight of 20 mice in 0.9% sodium chloride solution had tumor metastasis, while only 5 of 20 mice in nimesulide group had metastasis. The difference between the two groups was statistically significant (P <0.05). The mean microvessel density in the 0.9% sodium chloride solution group was 9.5 ± 2.9, and that in the nimesulide group was 3.9 ± 2.1. The difference between the two groups was statistically significant (P <0.05). The VEGF expression in 18 mice in 0.9% sodium chloride solution group was significantly higher than that in nimesulide group (P <0.05). Fluorescence quantitative PCR showed that the expression of VEGF mRNA in Nimesulide group (C t: 20.1 ± 2.0) was lower than that in 0.9% sodium chloride solution group (C t: 15.9 ± 1.8), the difference was statistically significant Shuli, P <0.05). Conclusions Nimesulide, a cyclooxygenase 2 inhibitor, inhibits tumor metastasis by inhibiting VEGF expression and angiogenesis, and nimesulide has no obvious hemorrhage and other adverse reactions.